NIKKEI 225
32,571.03 -452.75 (-1.37%) HANG SENG
17,655.41 -230.19 (-1.29%) CRUDE OIL
90.20 +0.54 (+0.60%) GOLD FUTURES
1,937.40 -29.70 (-1.51%) DOW
34,246.75 -194.13 (-0.56%) Bitcoin GBP
21,605.86 -477.60 (-2.16%)
Santhera Pharmaceuticals Holding AG (0QN1.L)
| Previous close | 8.52 |
| Open | 9.27 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 8.75 - 9.27 |
| 52-week range | 5.30 - 14.02 |
| Volume | |
| Avg. volume | 955 |
| Market cap | 996,060 |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireSanthera Announces Half-Year 2023 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 3.9 million (H1-2022: CHF 6.3 million)Operating result of CHF -20.3 million (H1-2022: CHF -25.5 million) and net result of CHF -23.3 million (H1-2022: CHF -29.7 million)Review of vamorolone's regulatory filings (NDA, MAA) for Duchenne muscular dystrophy (DMD) treatment proceeding as planned
- Globe Newswire
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
Ad hoc announcement pursuant to Art. 53 LR Chiesi Group acquires entire idebenone business including Raxone in Leber's hereditary optic neuropathy (LHON)Chiesi Group assumes French reimbursement liability of EUR 25.3 million from SantheraSanthera retains contingent value for LHON in U.S. and/or other indications worldwideSanthera ceases all Raxone-related activities and intensifies commercial preparation for Duchenne muscular dystrophy candidate vamorolone in Europe Pratteln, Switzerland, July 3
- Globe Newswire
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, July 19, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera’s cash reach into 2025. Together with the expected income from ongoing operations, it provides funding for the pre-commercialization and launch of vamorolo
